Clinical Trials Logo

Male Breast Cancer clinical trials

View clinical trials related to Male Breast Cancer.

Filter by:

NCT ID: NCT01939483 Withdrawn - Clinical trials for Stage IV Breast Cancer

A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases

Start date: December 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies irinotecan hydrochloride in treating patients with breast cancer and brain metastases that progressed after whole brain radiation therapy or stereotactic radiosurgery. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT01938833 Terminated - Clinical trials for Stage IV Breast Cancer

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of romidepsin when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with metastatic inflammatory breast cancer. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving romidepsin and paclitaxel albumin-stabilized nanoparticle formulation may be an effective treatment for inflammatory breast cancer.

NCT ID: NCT01931709 Terminated - Clinical trials for Stage IIIA Breast Cancer

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Start date: November 2011
Phase: N/A
Study type: Interventional

This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

NCT ID: NCT01869764 Completed - Clinical trials for Stage IIIA Breast Cancer

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.

NCT ID: NCT01868503 Terminated - Clinical trials for Stage IIIA Breast Cancer

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Start date: July 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lapatinib ditosylate and radiation therapy work in treating patients with locally advanced or locally recurrent breast cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving lapatinib ditosylate together with radiation therapy may be an effective treatment for breast cancer.

NCT ID: NCT01806675 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Start date: March 4, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

NCT ID: NCT01783756 Completed - Clinical trials for HER2-positive Breast Cancer

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

Start date: June 26, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2 study to evaluate the safety and clinical activity of the combination of lapatinib, everolimus and capecitabine for the treatment of participants with HER2+ breast cancer with metastases in the brain who have progressed on trastuzumab. The combination of 2 drugs able to reach the brain (lapatinib and everolimus) that target different parts of the HER2 signaling pathway plus chemotherapy (capecitabine) that has proven benefits in metastatic breast cancer may lead to improved clinical outcomes for participants with CNS metastasis. Participants will undergo brain MRIs and CT scans of the chest and abdomen to evaluate response to the treatment, regular laboratory tests and echocardiogram or Multi Gated Acquisition Scan (MUGA) to assess cardiac activity

NCT ID: NCT01729884 Terminated - Clinical trials for HER2-positive Breast Cancer

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well vaccine therapy works in treating patients with stage IV hormone receptor positive breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT01720602 Completed - Clinical trials for Stage IV Breast Cancer

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Start date: November 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.

NCT ID: NCT01706432 Active, not recruiting - Liver Metastases Clinical Trials

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Start date: June 15, 2009
Phase:
Study type: Observational

This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.